Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne CClin Infect Dis 2008[Feb]; 46 (4): 577-83The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Clinical studies comparing linezolid with 2 doses of dalbavancin have shown comparable efficacy for the treatment of skin and soft-tissue infection. Dalbavancin has also proven to be effective for therapy of catheter-related bloodstream infections. It has an excellent safety profile in studies to date. Dalbavancin will likely have a significant role in outpatient intravenous therapy for patients with potentially serious drug-resistant gram-positive coccal infections.|Anti-Bacterial Agents/adverse effects/*pharmacokinetics/*pharmacology[MESH]|Bacteremia/drug therapy[MESH]|Gram-Positive Bacterial Infections/*drug therapy[MESH]|Half-Life[MESH]|Humans[MESH]|Skin Diseases, Bacterial/drug therapy[MESH]|Soft Tissue Infections/drug therapy[MESH]|Teicoplanin/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology[MESH] |
